You are viewing the site in preview mode
Skip to main content
Author

Clinical target delineation and prescribed dose

Analyzed recurrent patients

Proportion of central recurrence


(year)

CTV1 (initial field)

CTV2 (boost field)


Brandes et al. [6]

Enhanced tumor area according to preoperative imaging plus 2–3 cm

None (identical with initial field)

79

72.2%^{a}

60 Gy in 30 fractions

Milano et al. [7]

Edema plus 2 cm

Residual tumor/resection cavity plus 2–2.5 cm

39

80%^{b}

46–50 Gy in 23–25 fractions

60 Gy in 30 fractions

Minniti et al. [8]

Residual tumor/resection cavity plus 2 cm

Residual tumor/resection cavity plus 1–2 cm

105

75.2%^{c}

50 Gy in 25 fractions

60 Gy in 30 fractions

McDonald et al. [9]

Edema plus 0.5–1.2 cm

Residual tumor/resection cavity plus 0–1 cm

41

78%^{d}

46–54 Gy in 23–30 fractions

60 Gy in 30 fractions

Dobelbower et al. [10]

Primary tumor and surrounding edema plus 0.5 cm on postoperative imaging

Residual tumor/resection cavity plus 0.5 cm

20

90%^{a}

60Gy in 30 fractions

46 Gy in 23 fractions

Present Study

Residual tumor/resection cavity plus 2 cm and edema

Residual tumor/resection cavity plus 0 cm

21

66.7%

50–54 Gy in 25–30 fractions

60 Gy in 30 fractions

 CTV: clinical target volume.
 ^{a}The term “central” was not actually used in the report. Instead, “infield” recurrence was defined as 80% of the tumor recurrence residing within the prescribed 95% isodose surface.
 ^{b}Central recurrence was defined as growth of the original tumor or arising tumor(s) from the resection cavity.
 ^{c}Central recurrence was defined as more than 95% of the recurrence volume within the 95% isodose line of 60 Gy.
 ^{d}Central recurrence was defined as more than 95% of the recurrence volume inside the 100% isodose line of 60 Gy.